Canton Strategic sells Gravitas Life Sciences for $3.5M note; focuses on Canton Network

Canton Strategic Holdings, Inc.

Sold 100% of Gravitas Life Sciences to Gravitas Collective Corp. for $3.5M unsecured promissory note (15% interest, matures July 2029) plus milestone payments.
Buyer affiliated with former directors Vincent LoPriore, Sireesh Appajosyula, Gary Stetz; transaction approved by special committee.
Company retains bispecific antibodies assets via Tharimmune SPV1; pro forma shows reduced operating losses (Q1 2026 net loss improves from $47.3M to $45.5M).
Divestiture aligns with transition to operating company driving digitization of financial markets via Canton Network; locking service launched June 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.